Cash and cash equivalents climbed to $196.6 million at June 30 from $79.4 million at Dec. 31, 2025.
Management cited momentum across partnered programs, including Crystalys’ $130 million Series B for dotinurad and royalties from ZYCUBO and UNLOXCYT launches.
Quarterly revenue rises as results turn to a loss
Fortress Biotech Q2 2026 revenue rose 14% to $18.7 million versus Q2 2025, with $17.8 million from marketed dermatology products.
Net loss attributable to common stockholders turned to $2.5 million, or $0.08 per share, from net income of $13.4 million a year earlier.
R&D expense fell to $0.8 million from $8.1 million, while SG&A dropped to $20.8 million from $38.8 million.
FBIO•
